A pharmacokinetic study of desmopressin - Minirin vs Sandoz

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521256-29-00

Enrollment

Registered

2025-06-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nocturnal enuresis

Brief summary

1) Area under the curve (AUC) (power based on this endpoint).

Detailed description

1) Plasmaconcentration (Cmax) 2) Time to maximum concentration (Tmax) 3) Urine osmolality (Uosm) 4) Urine output (uvol,ml 1) Taste 2) Textur 3) Preference

Interventions

DRUGDesmopressin "Sandoz"

DRUGsublinguale resoribletter

DRUGMinirin

DRUGfrysetørrede tabletter

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Secondary

Measure	Time frame
1) Plasmaconcentration (Cmax) 2) Time to maximum concentration (Tmax) 3) Urine osmolality (Uosm) 4) Urine output (uvol,ml 1) Taste 2) Textur 3) Preference	—

Primary

Measure	Time frame
1) Area under the curve (AUC) (power based on this endpoint).	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026